Mereo BioPharma Group plc (MREO) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Mereo BioPharma Group plc (MREO) Earnings Overview
As of June 28, 2026, Mereo BioPharma Group plc (MREO) reported trailing twelve-month net income of -$36M, reflecting +10.3% year-over-year growth. The company earned $-0.22 per diluted share over the past four quarters, with a net profit margin of -8375.6%.
Looking at the long-term picture, MREO's historical earnings data spans multiple years. The company achieved its highest annual net income of $17M in fiscal 2021.
Mereo BioPharma Group plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), KRYS ($225M net income, 52.6% margin), MREO has room to improve margins relative to the peer group. Compare MREO vs RARE →
MREO Earnings vs Peers
Earnings metrics vs comparable public companies
MREO Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$42M | +3.2% | -$38M | $-0.26 | -8375.6% | -7651.4% |
| 2024 | -$43M | -46.8% | -$47M | $-0.29 | - | - |
| 2023 | -$29M | +30.0% | -$28M | $-1100.22 | -294.7% | -284.2% |
| 2022 | -$42M | -345.3% | -$54M | $-1750.35 | - | - |
| 2021 | $17M | +108.2% | -$28M | $749.65 | 34.9% | -57.4% |
| 2020 | -$210M | -372.0% | -$48M | $-16503.30 | - | - |
| 2019 | -$44M | -38.8% | -$50M | $-12902.58 | - | - |
| 2018 | -$32M | +17.4% | -$35M | $-14352.87 | - | - |
| 2017 | -$39M | -36.7% | -$45M | $-19003.80 | - | - |
| 2016 | -$28M | - | -$36M | $-19553.91 | - | - |
Download Data
Export MREO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MREO — Frequently Asked Questions
Quick answers to the most common questions about buying MREO stock.
What is MREO earnings per share (EPS)?
MREO trailing twelve-month (TTM) diluted EPS is $-0.22, reflecting +10.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Mereo BioPharma Group plc's net income?
Mereo BioPharma Group plc (MREO) trailing twelve-month net income is $-36M as of 2025. Earnings grew +10.3% year-over-year.
Is MREO profitable?
MREO is not currently profitable on a TTM basis, reporting a net loss of $-36M. Net margin is -8375.6%. Investors should monitor for a return to profitability.
What is MREO's earnings growth rate?
MREO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are MREO's profit margins?
Mereo BioPharma Group plc net profit margin is -8375.6%, operating margin is -7651.4%, and gross margin is +73.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is -82.2%.
Is MREO growing earnings?
MREO is growing earnings steadily. YoY EPS growth of +10.3% is consistent with the 5-year CAGR of N/A. TTM net income is $-36M.
What was MREO's best earnings year?
Mereo BioPharma Group plc's highest annual net income on record is $17M, achieved in fiscal year 2021. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were MREO's earnings last quarter?
MREO's most recent reported quarter was Q1 2026. Net income was $-7M with diluted EPS of $-0.04. For a full breakdown of all quarters, see the quarterly earnings table on this page.